Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real-Life Italian Multicenter Harmonization Experience - PubMed
4 hours ago
- #MRD assessment
- #harmonization
- #multiple myeloma
- Measurable residual disease (MRD) assessment is crucial for evaluating treatment response in multiple myeloma (MM).
- The 'Italian MM-MRD network' project aimed to harmonize MRD evaluation across laboratories using Next-Generation Flow (NGF) and Next-Generation Sequencing (NGS).
- NGF workgroup achieved high inter-center concordance in monoclonal plasma cells detection (ICC = 0.90) and a median sensitivity of 8 × 10^-6.
- NGS workgroup focused on clonotypic IGH/IGK gene rearrangements, achieving 100% concordance in clonotype identification and 81-91% in MRD quantification.
- The study demonstrated feasibility of MRD harmonization, reducing variability and improving comparability for clinical use.